Latest News

The data come just days after the FDA approved IsoPSA to aid in the diagnosis of high-grade prostate cancer.

For micro-ultrasound compared with true cancer status, estimated sensitivity was 0.8000.

The HCPs and AHCPs described insertion and removal of the system to be “straightforward” and done in less than 5 minutes.

At a median follow-up of 25.8 months, the CR rate at any time was 75.5%.

The safety and efficacy of the Hugo RAS system for urologic procedures was established in the Expand URO IDE study.

The investigators reported that new onset of CNS-related conditions was lower in patients in the apalutamide cohort at 12 months and 24 months post index.

The approval is supported by 12-month data from the prospective VAPOR 2 trial.

At a median follow-up of 18.8 months, the confirmed ORR was 31%.

"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.

The test is intended to aid in the decision for prostate biopsy in men aged 50 years or older who present with elevated PSA levels.

In this episode, Farnoosh Nik-Ahd, MD, joins host Adam Weiner, MD, to discuss emerging guidance on prostate cancer screening in transgender women.

"Based on the code description, we recommend basing the code selection on the documentation and the effort required to complete the service, and not the number of foreign bodies removed from the bladder," write Jonathan Rubenstein, MD, and Mark Painter.

"Site neutrality is a pivotal issue for all independent practices, and really, it's a pivotal issue for all Americans because it affects both the global cost of care as well as the acceleration and the cost of care," says Mara R. Holton, MD.